Table 2. Main clinical characteristics of the patients enrolled in our study at castration resistance onset.
| Patients | Age | Recruitment criterion | PSA (ng/mL) | CgA (ng/mL) | 68GA-DOTANOC uptake |
|---|---|---|---|---|---|
| 1 | 49 | Multiple bone metastases | 5 | 289 | Bone |
| 2 | 61 | Multiple bone metastases | 20 | 13 | Negative |
| 3 | 61 | Raising PSA | 21 | NA | Negative |
| 4 | 71 | Multiple bone metastases | 246 | NA | Negative |
| 5 | 59 | Bone metastases + lung lymphangitis | 4 | 1, 5 | Bone, lung |
| 6 | 55 | Multiple bone metastases | 5 | 2,400 | Negative |
PSA, prostate-specific antigen; CgA, chromogranin A.